| REGENTS-OF-THE-UNIVERSITY-OF-MINNESOTA |
REGENTS-OF-THE-UNIVERSITY-OF-MINNESOTA |
92%
|
On April 3, 2026, GT Biopharma, Inc., a Delaware corporation (the “Company”), entered into an Investigator Initiated Clinical Trial Agreement (the “Agreement”) with the Regents of the University of M… |
| DDI-PHARMACEUTICALS-INC |
DDI-PHARMACEUTICALS-INC |
62%
|
rued expenses 937,000 1,962,000 (Decrease) in operating lease liability ( 58,000 ) ( 116,000 ) Net Cash Used in Operating Activities ( 12,904,000 ) ( 8,852,000 ) CASH FLOWS FROM INVESTING ACTIVITIES … |
| DIAGNOSTIC-DATA-INC |
DIAGNOSTIC-DATA-INC |
62%
|
rued expenses 937,000 1,962,000 (Decrease) in operating lease liability ( 58,000 ) ( 116,000 ) Net Cash Used in Operating Activities ( 12,904,000 ) ( 8,852,000 ) CASH FLOWS FROM INVESTING ACTIVITIES … |
| GEORGETOWN-TRANSLATIONAL-PHARMACEUTICALS-INC |
GEORGETOWN-TRANSLATIONAL-PHARMACEUTICALS-INC |
62%
|
. The GT Biopharma logo, TriKE®, and other trademarks or service marks of GT Biopharma, Inc. appearing in this quarterly report are the property of the Company. This Annual Report on Form 10-K also c… |
| GOING-CONCERN-ANALYSIS-ORGANIZATION-GT-BIOPHARMA |
GOING-CONCERN-ANALYSIS-ORGANIZATION-GT-BIOPHARMA |
62%
|
uance of inducement warrants for cash, net 1,052,000 — Proceeds from issuance of common stock and warrants, net - 2,976,000 Proceeds from issuance of Series L convertible preferred stock and warrants… |
| GT-BIOPHARMA-INC-DIAGNOSTIC-DATA-INC |
GT-BIOPHARMA-INC-DIAGNOSTIC-DATA-INC |
62%
|
rrant liability ( 11,000 ) ( 126,000 ) Changes in operating assets and liabilities: (Increase) Decrease in prepaid expenses 222,000 ( 12,000 ) Increase (Decrease) in accounts payable and accrued expe… |
| INTERNATIONAL-BIOCLINICAL-INC |
INTERNATIONAL-BIOCLINICAL-INC |
62%
|
rued expenses 937,000 1,962,000 (Decrease) in operating lease liability ( 58,000 ) ( 116,000 ) Net Cash Used in Operating Activities ( 12,904,000 ) ( 8,852,000 ) CASH FLOWS FROM INVESTING ACTIVITIES … |
| OXIS-BIOTECH-INC |
OXIS-BIOTECH-INC |
62%
|
. The GT Biopharma logo, TriKE®, and other trademarks or service marks of GT Biopharma, Inc. appearing in this quarterly report are the property of the Company. This Annual Report on Form 10-K also c… |
| OXIS-INTERNATIONAL-INC |
OXIS-INTERNATIONAL-INC |
62%
|
rued expenses 937,000 1,962,000 (Decrease) in operating lease liability ( 58,000 ) ( 116,000 ) Net Cash Used in Operating Activities ( 12,904,000 ) ( 8,852,000 ) CASH FLOWS FROM INVESTING ACTIVITIES … |
